BioMarin Pharmaceutical (NASDAQ:BMRN) Updates FY 2024 Earnings Guidance

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided EPS guidance of 2.750-2.950 for the period, compared to the consensus EPS estimate of 1.650. The company issued revenue guidance of $2.7 billion-$2.8 billion, compared to the consensus revenue estimate of $2.8 billion. BioMarin Pharmaceutical also updated its FY24 guidance to $2.75-2.95 EPS.

BioMarin Pharmaceutical Stock Down 0.9 %

NASDAQ BMRN traded down $0.86 during trading hours on Wednesday, hitting $91.20. 1,599,318 shares of the company were exchanged, compared to its average volume of 1,355,438. BioMarin Pharmaceutical has a 52-week low of $76.02 and a 52-week high of $99.56. The company has a 50 day moving average of $87.76 and a two-hundred day moving average of $89.21. The company has a quick ratio of 1.57, a current ratio of 2.51 and a debt-to-equity ratio of 0.12. The firm has a market cap of $17.21 billion, a price-to-earnings ratio of 104.61, a PEG ratio of 1.65 and a beta of 0.31.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last posted its quarterly earnings data on Thursday, February 22nd. The biotechnology company reported $0.49 EPS for the quarter, topping analysts' consensus estimates of $0.44 by $0.05. BioMarin Pharmaceutical had a return on equity of 5.01% and a net margin of 6.93%. The company had revenue of $646.21 million for the quarter, compared to the consensus estimate of $639.53 million. During the same quarter in the previous year, the business earned $0.11 EPS. The company's quarterly revenue was up 20.2% compared to the same quarter last year. Equities research analysts anticipate that BioMarin Pharmaceutical will post 1.85 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on BMRN shares. Cantor Fitzgerald reiterated an overweight rating and set a $100.00 price objective on shares of BioMarin Pharmaceutical in a research note on Friday, February 23rd. Royal Bank of Canada reissued a sector perform rating and set a $100.00 price objective on shares of BioMarin Pharmaceutical in a report on Friday, February 23rd. Canaccord Genuity Group reissued a hold rating and set a $91.00 target price on shares of BioMarin Pharmaceutical in a research note on Thursday, February 29th. Piper Sandler decreased their price target on BioMarin Pharmaceutical from $115.00 to $107.00 and set an overweight rating for the company in a research report on Friday, February 23rd. Finally, Robert W. Baird reduced their price target on shares of BioMarin Pharmaceutical from $127.00 to $104.00 and set an outperform rating on the stock in a research report on Tuesday, January 30th. Seven analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, BioMarin Pharmaceutical has an average rating of Moderate Buy and an average price target of $107.61.

Insider Buying and Selling

In related news, insider Henry J. Fuchs sold 35,341 shares of the business's stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $85.18, for a total value of $3,010,346.38. Following the sale, the insider now owns 212,117 shares in the company, valued at approximately $18,068,126.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, insider Henry J. Fuchs sold 35,341 shares of the firm's stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $85.18, for a total value of $3,010,346.38. Following the sale, the insider now directly owns 212,117 shares in the company, valued at approximately $18,068,126.06. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Jean Jacques Bienaime sold 1,000 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $85.51, for a total value of $85,510.00. Following the completion of the transaction, the director now directly owns 561,203 shares in the company, valued at $47,988,468.53. The disclosure for this sale can be found here. Insiders have sold 103,229 shares of company stock valued at $9,062,967 over the last quarter. Corporate insiders own 1.84% of the company's stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.